| Participants with LC |  | |
---|---|---|---|
 | Screen-detected (n = 34) | Nonscreen-detected (n = 33) | P |
Age, median (IQR) | 66 (60-71) | 69 (59-72) | 0.965 |
Male/female (ratio) | 30/4 (7.5) | 30/3 (10) | 0.721 |
Pack-years, median (IQR) | 55 (39-77)a | 46 (33-76)b | 0.200 |
Histologically confirmed LC, n (%) | 34 (100%) | 29 (88%) | 0.036 |
   Adenocarcinoma, n (%) | 11 (32%) | 6 (21%) |  |
   Squamous cell carcinoma, n (%) | 16 (47%) | 12 (41%) | 0.618 |
   Other NSCLC, n (%) | 3 (9%) | 4 (14%) |  |
   SCLC, n (%) | 4 (12%) | 7 (24%) |  |
Stage of LC at diagnosis c | Â | Â | Â |
   I, n (%) | 18 (53%) | 3 (9%) |  |
   II, n (%) | 2 (6%) | 1 (3%) |  |
   IIIA, n (%) | 5 (15%) | 4 (12%) | < 0.0001 |
   IIIB-IV and extensive SCLC, n (%) | 7 (21%) | 25 (76%) |  |
   Indeterminate, n (%)* | 2 (6%) | 0 |  |
Follow-up months, median (range) d | 100 (49-161) | 72 and 98e | - |